4Shaha AR.Controversies in the management of thyroid nodule[J].Laryngoscope,2000,110(2Pt1):183-193.
5Werga P,Wallin G,Skoog L,et al.Expanding role of fine needle aspiration cytology in thyroid diagnosis and management[ J ].World J Surg,2000,24 (8):907-909.
7Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53 856 cases of thyroid carcinoma treated in the U. S, 1985-1995 [J]. Cancer, 1998, 83(12): 2638-2648.
8Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations [J]. Surg Oncol Clin NAm, 1996, 5(1): 43-63.
9Scheumann GF, Gimm O, Wegener G, et al. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer [J]. World J Surg, 1994, 18(4): 559-568.
10Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carci- noma managed at the Mayo Clinic during six decades (1940-1999) temporal trends in initial therapy and long-term outcome in 2 444 consecutively treated patients [J]. World J Surg, 2002, 26(8): 879-885.
4Kebebew E,Ituarte PH,Siperstein AE,et al. Medullary thyroid car-cinoma: clinical characteristics, treatment, prognostic factors, and acomparison of staging systems [ J ]. Cancer, 2000,88 ( 5 ) : 1139-1148.
5Hofstra RM,Landsvater RM,Ceccherini I,et al. A mutation in theRET proto-oncogene associated with multiple endocrine neoplasiatype 26 and sporadic medullary thyroid carcinoma [ J]. Nature,1994,367(6461) :375 -376.
6Castellone MD, Santoro M. Dysregulated RET signaling in thyroidcancer[ J]. Endocrinol Metab Clin North Am, 2008,37 (2) : 363-374.
7Yang KP,Castillo SG,Nguyen CV,et al. C-myc,N-myc,N-ras,andc-erb-B :lack of amplification or rearrangement in human medullarythyroid carcinoma and a derivative cell line[ J]. Anticancer Res,1990,10(1) :189 -92.
8Yana I,Nakamura T,Shin E,et al. Inactivation of the p53 gene isnot required for tumorigenesis of medullary thyroid carcinoma orpheochromocytoma [ J ]. Jpn J Cancer Res, 1992, 83 ( 11 ):1113-1116.
